Because “age-related macular degeneration” (AMD) is the leading cause of vision loss and blindness in Americans aged 65 years and older, any information about a potential new treatment is welcomed. As a starting point in searching for new ways to treat AMD, researchers noted that people with highly pigmented and darker-colored eyes are less prone to developing AMD and more likely to have higher levels of a chemical called L-DOPA, which is prescribed to Parkinson’s patients (who have low levels of this dopamine precursor in their brains).
When researchers examined the records of people prescribed L-DOPA, they found that they were less likely to develop AMD, and when they did, it began much later. Clinical trials will follow. Age-related macular degeneration (AMD) affects the central portion of the retina (macula), which is responsible for seeing the center of the visual field and fine detail.
Call Susskind & Almallah Eye Associates at 732-349-5622 today to schedule your consultation with one of our experienced doctors. We proudly serve the areas of Marlboro, Toms River, Brick, and Barnegat, New Jersey.